奥西替尼联合化疗一线治疗EGFR-RAD51融合突变转移性肺腺癌1例

doi:10.6040/j.issn.1671-7554.0.2023.0921

摘要/Abstract

中图分类号:

R734

张荣雨,赵文,李洪欣,杨闯,王健,韩春燕,李际盛. 奥西替尼联合化疗一线治疗EGFR-RAD51融合突变转移性肺腺癌1例[J]. 山东大学学报 (医学版), 2024, 62(5): 116-120.

[1] Gahr S, Stoehr R, Geissinger E, et al. EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice[J]. Br J Cancer, 2013, 109(7): 1821-1828.
[2] 邹琳, 邵伟伟, 李蕾,等. 非小细胞肺癌患者EGFR\ALK\ROS1基因突变状态及其临床意义[J]. 诊断病理学杂志, 2020, 27(2): 85-89. ZOU Lin, SHAO Weiwei, LI Lei, et al. EGFR, ALK and ROS1 gene mutations and their clinical significance in non-small cell lung carcinoma[J]. Chinese Journal of Diagnostic Pathology, 2020, 27(2): 85-89.
[3] Russo A, Lopes AR, McCusker MG, et al. New targets in lung cancer(excluding EGFR, ALK, ROS1)[J]. Curr Oncol Rep, 2020, 22(5): 48. doi: 10.1007/s11912-020-00909-8.
[4] Kohno T, Nakaoku T, Tsuta K, et al. Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer[J]. Transl Lung Cancer Res, 2015, 4(2): 156-164.
[5] Kim M, Jeong JY, Park NJ, et al. Clinical utility of next-generation sequencing in real-world cases: a single-institution study of nine cases[J]. In Vivo, 2022, 36(3): 1397-1407.
[6] Pecciarini L, Brunetto E, Grassini G, et al. Gene fusion detection in NSCLC routine clinical practice: targeted-NGS or FISH?[J]. Cells, 2023, 12(8): 1135. doi: 10.3390/cells12081135.
[7] Konduri K, Gallant JN, Chae YK, et al. EGFR fusions as novel therapeutic targets in lung cancer[J]. Cancer Discov, 2016, 6(6): 601-611.
[8] Di Federico A, Filetti M, Palladini A, et al. EGFR-RAD51 gene fusion NSCLC responsiveness to different generation EGFR-TKIs: two cases and review of the literature[J]. Transl Lung Cancer Res, 2022, 11(3): 497-503.
[9] Raez LE, Pinto JA, Schrock AB, et al. EGFR-RAD51 fusion: a targetable partnership originated from the tumor evolution?[J]. J Thorac Oncol, 2018, 13(3): e33-e34.
[10] Guan Y, Song Z, Li Y, et al. Effectiveness of EGFR-TKIs in a patient with lung adenocarcinoma harboring an EGFR-RAD51 fusion[J]. Oncologist, 2019, 24(8): 1027-1030.
[11] Zhu YC, Wang WX, Xu CW, et al. EGFR-RAD51 fusion variant in lung adenocarcinoma and response to erlotinib: a case report[J]. Lung Cancer, 2018, 115: 131-134. doi: 10.1016/j.lungcan.2017.12.001.
[12] Zhang G, Xia P, Zhao S, et al. Gefitinib combined with cetuximab for the treatment of lung adenocarcinoma harboring the EGFR-intergenic region(SEC61G)fusion and EGFR amplification[J]. Oncologist, 2021, 26(11): e1898-e1902.
[13] Copia Sperandio R, Luiza Teixeira Tostes F, Vidal Campregher P, et al. EGFR-RAD51 fusion in lung adenocarcinoma with systemic and intracranial response to osimertinib: a case report and review of the literature[J]. Lung Cancer, 2022, 166: 94-97. doi: 10.1016/j.lungcan.2022.02.006.
[14] Zhong R, Li H, Liu Y, et al. Chemotherapy combined with bevacizumab for the treatment of advanced lung adenocarcinoma cancer harboring EGFR-ANXA2, EGFR-RAD51, ATR and BRCA2 mutations: a case report[J]. Thorac Cancer, 2020, 11(2): 456-460.
[15] Wang X, Huang L, Cai J, et al. A novel KIF5B-EGFR fusion variant in non-small-cell lung cancer and response to afatinib: a case report[J]. Onco Targets Ther, 2021, 14: 3739-3744. doi: 10.2147/OTT.S313896.
[16] Xu H, Shao C. KIF5B-EGFR fusion: a novel EGFR mutation in lung adenocarcinoma[J]. Onco Targets Ther, 2020, 13: 8317-8321. doi: 10.2147/OTT.S263994.
[17] Zhu YC, Wang WX, Li XL, et al. Identification of a novel icotinib-sensitive EGFR-SEPTIN14 fusion variant in lung adenocarcinoma by next-generation sequencing[J]. J Thorac Oncol, 2019, 14(8): e181-e183.
[18] Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer[J]. N Engl J Med, 2018, 378(2): 113-125.
[19] Colclough N, Chen K, Johnström P, et al. Preclinical comparison of the blood-brain barrier permeability of osimertinib with other EGFR TKIs[J]. Clin Cancer Res, 2021, 27(1): 189-201.
[20] Saito R, Sugawara S, Ko R, et al. Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: the OPAL study[J]. Eur J Cancer, 2023, 185: 83-93. doi: 10.1016/j.ejca.2023.02.023.

相关文章 15

[1]	韩明勇,于晓黎,曾放平,谢兵,芦兰,瞿家权,江璧锋,唐斯晗,谭洁,梁瑾,钟龙辉,王柳,赵宣植. CT引导经皮肺穿刺肿瘤内化疗技术流程[J]. 山东大学学报 (医学版), 2023, 61(11): 11-19.
[2]	阮祥燕,程姣姣,杜娟,谷牧青. 卵巢组织冷冻保存[J]. 山东大学学报 (医学版), 2022, 60(9): 24-30.
[3]	秦静,杨飞,陈谦,夏涵岱,刘延国,王秀问. 晚期驱动基因阴性、PD-L1表达阴性非鳞非小细胞肺癌一线治疗方案的网状Meta分析[J]. 山东大学学报 (医学版), 2022, 60(7): 74-82.
[4]	陈兆波,方敏,薛浩然,刘春艳. 去泛素化酶USP35促进非小细胞肺癌细胞迁移和侵袭[J]. 山东大学学报 (医学版), 2022, 60(4): 30-37.
[5]	马瑞杰,朱良明,左太阳,李春海,张楠,孙志钢. 微波消融治疗非小细胞肺癌根治术后肺寡转移瘤的预后分析[J]. 山东大学学报 (医学版), 2022, 60(12): 63-68.
[6]	刘会宁,彭军,任迎春,杨光,王文豪,刘金锋,田勍. 34例胸腔镜下肺楔形切除与21例肺段切除对位于肺段P区的ⅠA1期非小细胞肺癌治疗比较[J]. 山东大学学报 (医学版), 2022, 60(11): 38-43.
[7]	丁子琛,王浩桦,周立雯,丛慧文,李承圣,包绮晗,杨毅,王廉源,王素珍,石福艳. 基于贝叶斯累加回归树模型的非小细胞肺癌患者个性化疗效研究[J]. 山东大学学报 (医学版), 2022, 60(10): 92-98.
[8]	初竹秀,赵文静,李小燕,孔晓丽,马婷婷,江立玉,杨其峰. 218例女性乳腺癌患者行新辅助化疗及伴随分子标志物改变的临床价值[J]. 山东大学学报 (医学版), 2021, 59(9): 130-139.
[9]	郭田,付依林,高聆,宋勇峰,付国斌,耿冲,王潍博. 142例女性乳腺癌患者临床特征与甲状腺激素水平的关联分析[J]. 山东大学学报 (医学版), 2020, 58(6): 53-59.
[10]	陈荣,李海超,赵健. 原发性纵隔精原细胞瘤1例报告及文献复习[J]. 山东大学学报 (医学版), 2020, 58(2): 79-84.
[11]	张喜琴,祝守慧,刘宁,王玉,陈家帧,胡旭东. PEG-rhG-CSF对80例小细胞肺癌同步放化疗预防中性粒细胞减少的临床观察[J]. 山东大学学报 (医学版), 2020, 58(12): 43-46.
[12]	刘小璟,夏西燕,肖珂,陈文丹,庄学伟. 外泌体lncRNA OGFRP1在84例非小细胞肺癌中的表达及临床意义[J]. 山东大学学报 (医学版), 2020, 58(11): 71-75.
[13]	魏萍,杜鲁涛,王卿,展垚,谢玉姣,张淑君,段伟丽,王传新. 血清外泌体miR-20b-5p对非小细胞肺癌的诊断价值[J]. 山东大学学报 (医学版), 2019, 57(4): 91-96.
[14]	王伟,刘拥征,李岭. 酸浆苦素B对人非小细胞肺癌细胞增殖、迁移及凋亡的影响[J]. 山东大学学报 (医学版), 2019, 57(3): 13-18.
[15]	侯巧妮,马会明,相丽,何艳桃,徐仙,陈冬梅,张雪玉. 人胎盘间充质干细胞移植对化疗所致卵巢早衰大鼠卵巢功能的影响[J]. 山东大学学报 (医学版), 2019, 57(2): 52-60.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed